Quantcast

Latest Morpholines Stories

2010-03-09 09:30:00

LAWRENCEVILLE, N.J., March 9 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will...

56a2b42491908ae0714aac35ed4f3a801
2010-01-19 13:45:40

Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell. The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce...

2010-01-19 00:01:00

CHAPEL HILL, N.C., Jan. 19 /PRNewswire/ -- Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections. The Phase 2/3 trial uses an adaptive-design in which the Phase 2 portion enrolled 180 patients with acute cellulitis or wound infections into one of the three arms: a conventional twice daily TAKSTA regimen, a novel...

3eec8da6a58c8dbc8d08e7d2634eff8b1
2009-12-24 07:15:00

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer. In a study to be published in the December 24/31 issue of the journal Nature, the researchers report that non-small cell lung cancers that had become invulnerable to the drugs Iressaâ and Tarcevaâ were stymied by a compound...

2009-12-09 17:41:02

Drug resistant lung cancer cells change their behavior in ways we do not understand to evade treatment, but these events can now be recapitulated and studied in mice Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR). Lung cancer with changes in EGFR is initially treatable with a family of chemotherapeutic agents...

2009-11-06 02:00:00

PARIS, November 6 /PRNewswire/ -- - Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical...

2009-10-28 23:01:00

CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia. Susceptibility of CEM-101 and more than 25 other antibiotics was tested against 1,737 multidrug-resistant S. pneumoniae strains collected in 2008 from medical centers in the U.S., Europe and Latin America. CEM-101 demonstrated...

2009-09-12 13:30:00

SAN DIEGO, Sept. 12 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA. Additional data from a previously announced Phase 2 study of torezolid (TR-701) reiterate the high efficacy of...

2009-07-27 15:20:00

The cause of lung cancer in never-smokers is poorly understood, but a study led by investigators at the Ohio State University Comprehensive Cancer Center and at the National Cancer Institute has identified a molecule believed to play an early and important role in its development.The findings, published online recently in the Proceedings of the National Academy of Sciences, may lead to improved therapy for lung cancer in both never-smokers and smokers, including those with tumors resistant to...

2009-06-30 10:47:00

Award Recognizes Entrepreneurial Excellence LAWRENCEVILLE, N.J., June 30 /PRNewswire/ -- Aton Pharma, Inc. announced today that its Chief Executive Officer, Michael G. Wells, has received the Ernst & Young Entrepreneur Of The Year(R) 2009 Award in the emerging companies category in New Jersey. According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. Mr. Wells was selected by an independent panel of...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related